“Novo Nordisk's Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish drugmaker said Monday.
The pill -- a tablet formulation of its Wegovy shot -- is now available through over 70,000 U.S. pharmacies such as CVS and Costco, and telehealth providers including Ro, LifeMD, Weight Watchers, NovoCare Pharmacy and GoodRx, among others.
The company's shares rose 5% in European trade on Monday and have risen 14% since U.S. FDA approval was granted on Dec. 22.
The once-daily pill is the first GLP-1 weight-loss pill to hit the market, with Eli Lilly only recently filing for U.S. approval of its own GLP-1 weight-loss tablet.
The Wegovy pill is being sold at a cash price of $149 a month for the starting dose of 1.5 milligrams. The 4-milligram dose will also be available for $149 a month through April 15, before rising to $199 a month later.
The highest 9-milligram and 25-milligram doses will be available for $299 a month, it said.
Trials of the Wegovy pill have shown patients can lose an average of 16.6% of their weight after 64 weeks of consistent use, when used with a reduced-calorie diet and exercise.” [1]
1. U.S. Access Grows For Wegovy Pill. Chopping, Dominic. Wall Street Journal, Eastern edition; New York, N.Y.. 06 Jan 2026: B3.
Komentarų nėra:
Rašyti komentarą